J Korean Pediatr Soc.  1998 Feb;41(2):209-215.

Induction Chemotherapy with BH-AC, Idarubicin, and 6-Thioguanine in Childhood Acute Myelogenous Leukemia

• Han HJ
• Kang HJ
• Lee JA
• Choi HS
• Park HJ
• Seong KW
• Yoo ES
• Shin HY
• Ahn HS

Abstract

PURPOSE
We have undertaken this study to evaluate the effects of induction chemotherapy involving BH-AC, idarubicin, and 6-thioguanine (6-TG).
METHODS
BH-AC 300mg/m2/day was administered intravenously over three hours for seven consecutive days. Idarubicin 12mg/m2/day was administered intravenously for three days. 6-TG 100 mg/m2/day was administered orally for seven days. Intrathecal ara-C was administered on the first day of treatment.
RESULTS
Complete remission (CR) was achieved in 18 cases (66.7%), partial remission (PR) was achieved in 2 cases (7.4%). In previously untreated patients, complete reimission rate was 92.9% (13/ 14), in relapsed patients, 40% (2/5) and in the refractory patients, 37.5% (3/8). The remission duration until December 1996 was 45 to 630 days (median 133). Duration of the neutropenia (ANC<500/microliter) was 0 to 38 days (median 24). Side effects were nausea, vomiting (7/27, 25.9%), liver dysfunction (1/27, 3.7%), skin eruption (1/27, 3.7%), and mucositis (1/27, 3.7%). In all cases, fever developed in the neutropenic state (culture proven sepsis in 5 cases). Death occurred in 5 cases who achieved CR due to sepsis after chemotherapy (4 cases), intracerebral hemorrhage after bone marrow relapse (1 case).
CONCLUSION
BH-AC, idarubicin, and 6-TG induction chemotherapy could be a useful induction chemotherapy treatment that combines supportive care for infection and bleeding.

Keyword

BH-AC; Idarubicin; Induction chemotherapy; Remission rate; Acute myelogenous leukemia

MeSH Terms

Bone Marrow
Cerebral Hemorrhage
Cytarabine
Drug Therapy
Fever
Hemorrhage
Humans
Idarubicin*
Induction Chemotherapy*
Leukemia, Myeloid, Acute*
Liver Diseases
Mucositis
Nausea
Neutropenia
Recurrence
Sepsis
Skin
Thioguanine*
Vomiting
Cytarabine
Idarubicin
Thioguanine